Harrow's CEO, Mark Baum, transformed the company from a struggling OTC penny stock to a leader in ophthalmic compounding drugs, emphasizing accessible healthcare. Harrow's business model includes a ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results